Discover and read the best of Twitter Threads about #NMIBC
Most recents (3)
There is an unmet need for effective treatments for #BladderCancer, especially for advanced stages of the disease.
Innovative treatments for bladder cancer have the potential to capture a significant share of the market.
Innovative treatments for bladder cancer have the potential to capture a significant share of the market.
Bladder #cancer is a common and costly disease, with over 600,000 new cases diagnosed worldwide each year. This high prevalence of the disease creates a large potential market for treatments.
Saw this article on #Theralase in @YahooFinance:
finance.yahoo.com/news/theralase…
Saw this article on #Theralase in @YahooFinance:
finance.yahoo.com/news/theralase…
Theralase is a biotech company focused on the research, development, and commercialization of advanced medical technologies, with the potential to be used in a wide range of medical applications, including the treatment of cancer, arthritis, and other diseases
What do you think?
What do you think?
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022:
Some negative, some positive, but we learned from all!
Feel free to add more & retweet & tag anyone involved
This is not an exhaustive list!
@OncoAlert @DanaFarber
#OnwardFor2023
Some negative, some positive, but we learned from all!
Feel free to add more & retweet & tag anyone involved
This is not an exhaustive list!
@OncoAlert @DanaFarber
#OnwardFor2023
1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval.
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10…
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10…
2/ In #PCa patients with detectable PSA after prostatectomy, lymph node RT + ADT+ PBRT⬆️freedom from progression compared to ADT+ PBRT and PBRT alone according to #SPPORT trial.
@_APollack @DrHowardSandler @TheLancet
thelancet.com/journals/lance…
@_APollack @DrHowardSandler @TheLancet
thelancet.com/journals/lance…
@TheWonkologist: All great & valid points, IMHO we as a #bladdercancer community are just so desperate for an alternative to cystectomy & @FDAOncology already set the bar so low with approval of Pembro in this space that Adstiladrin will almost certainly be FDA approved 1/n
Hopefully, patients declining RC still preferentially go on trials, but with urologists more comfortable managing urinary AEs over IO AEs, Adstiladrin will likely get a higher market share over Pembro (but Gem, GemDoce, MMC might still be used more than both) 2/n
With every drug in this space all showing ~40% 3 m CRs & ~20% 12 m CRs, I worry this is just the natural history of BCG unresponsive #NMIBC. Some slides from a recent talk I gave to @UrologyMSK @SUO_YUO fellows 3/n
